Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Karolinska Development AB ( (SE:KDEV) ) has provided an announcement.
Karolinska Development’s portfolio company, PharmNovo, has received approval from Spanish regulatory authorities to initiate a phase 2a clinical trial for its drug candidate, PN6047, aimed at treating neuropathic pain. This trial, aligned with FDA requirements, marks a significant step in developing a potential new treatment for severe pain without the addiction risks associated with traditional opioids, highlighting Karolinska Development’s strategic focus on innovative medical solutions.
More about Karolinska Development AB
Karolinska Development AB is a Nordic life sciences investment company that focuses on identifying and investing in breakthrough medical innovations in the Nordic region. The company aims to advance these innovations into commercial products that improve patients’ lives while providing attractive returns to shareholders. With access to world-class medical innovations from the Karolinska Institutet and other leading research institutes, Karolinska Development supports the growth of companies targeting innovative treatments for serious diseases.
Average Trading Volume: 305,378
Current Market Cap: SEK237.5M
Learn more about KDEV stock on TipRanks’ Stock Analysis page.